<?xml version='1.0' encoding='utf-8'?>
<document id="31288895"><sentence text="A new similarity method for assessment of pharmacokinetic interaction between flucloxacillin and midazolam."><entity charOffset="78-92" id="DDI-PubMed.31288895.s1.e0" text="flucloxacillin" /><entity charOffset="97-106" id="DDI-PubMed.31288895.s1.e1" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.31288895.s1.e0" e2="DDI-PubMed.31288895.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31288895.s1.e0" e2="DDI-PubMed.31288895.s1.e1" /></sentence><sentence text="The purpose of this study was to develop a new similarity method to assess the drug-drug interaction between midazolam and flucloxacillin"><entity charOffset="109-118" id="DDI-PubMed.31288895.s2.e0" text="midazolam" /><entity charOffset="123-137" id="DDI-PubMed.31288895.s2.e1" text="flucloxacillin" /><pair ddi="false" e1="DDI-PubMed.31288895.s2.e0" e2="DDI-PubMed.31288895.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31288895.s2.e0" e2="DDI-PubMed.31288895.s2.e1" /></sentence><sentence text=" Total quantum statistical moment (TQSM) of pharmacokinetic profiles were expressed by parameters AUCT, MRTT, VRTT et al" /><sentence text=" Statistical moment similarity (SMS) expressions were deduced to evaluate the similarity of the converted pharmacokinetic profiles" /><sentence text=" A trial of the pharmacokinetic interaction between midazolam and flucloxacillin by the SMS method was conducted"><entity charOffset="52-61" id="DDI-PubMed.31288895.s5.e0" text="midazolam" /><entity charOffset="66-80" id="DDI-PubMed.31288895.s5.e1" text="flucloxacillin" /><pair ddi="false" e1="DDI-PubMed.31288895.s5.e0" e2="DDI-PubMed.31288895.s5.e0" /><pair ddi="false" e1="DDI-PubMed.31288895.s5.e0" e2="DDI-PubMed.31288895.s5.e1" /></sentence><sentence text=" For midazolam, total quantum SMS (SMST) was 0" /><sentence text="9582; total deviation was 0" /><sentence text="0525; total variable probability was 4" /><sentence text="18 %; total confidence of probability β was 97" /><sentence text="17 % under significance level 0" /><sentence text="05; AUC0-∞ were 334" /><sentence text="3±334" /><sentence text="1 ng•h•mL-1 (after administration of midazolam alone) and 206"><entity charOffset="37-46" id="DDI-PubMed.31288895.s13.e0" text="midazolam" /></sentence><sentence text="9±172" /><sentence text="2 ng•h•mL-1 (after co-administration of midazolam and flucloxacillin), respectively"><entity charOffset="40-49" id="DDI-PubMed.31288895.s15.e0" text="midazolam" /><entity charOffset="54-68" id="DDI-PubMed.31288895.s15.e1" text="flucloxacillin" /><pair ddi="false" e1="DDI-PubMed.31288895.s15.e0" e2="DDI-PubMed.31288895.s15.e0" /><pair ddi="false" e1="DDI-PubMed.31288895.s15.e0" e2="DDI-PubMed.31288895.s15.e1" /></sentence><sentence text=" While, for 1'-hydroxy midazolam, SMST was 0"><entity charOffset="12-32" id="DDI-PubMed.31288895.s16.e0" text="1'-hydroxy midazolam" /></sentence><sentence text="6920; total deviation was 0" /><sentence text="3960; total variable probability was 30" /><sentence text="80 %; total confidence of probability β was 94" /><sentence text="10 % under significance level 0" /><sentence text="05; AUC0-∞ were 1364±810" /><sentence text="7 ng•h•mL-1 (after administration of midazolam alone) and 1637±632"><entity charOffset="37-46" id="DDI-PubMed.31288895.s22.e0" text="midazolam" /></sentence><sentence text="6 ng•h•mL-1 (after co-administration of midazolam and flucloxacillin), respectively"><entity charOffset="40-49" id="DDI-PubMed.31288895.s23.e0" text="midazolam" /><entity charOffset="54-68" id="DDI-PubMed.31288895.s23.e1" text="flucloxacillin" /><pair ddi="false" e1="DDI-PubMed.31288895.s23.e0" e2="DDI-PubMed.31288895.s23.e0" /><pair ddi="false" e1="DDI-PubMed.31288895.s23.e0" e2="DDI-PubMed.31288895.s23.e1" /></sentence><sentence text=" These results revealed that flucloxacillin might have weak pharmacokinetic interactions on midazolam metabolized into 1'-hydroxy midazolam, indicating that there was weak induction to CYP3A by flucloxacillin and that there was at least 30"><entity charOffset="29-43" id="DDI-PubMed.31288895.s24.e0" text="flucloxacillin" /><entity charOffset="119-139" id="DDI-PubMed.31288895.s24.e1" text="1'-hydroxy midazolam" /><entity charOffset="194-208" id="DDI-PubMed.31288895.s24.e2" text="flucloxacillin" /><pair ddi="false" e1="DDI-PubMed.31288895.s24.e0" e2="DDI-PubMed.31288895.s24.e0" /><pair ddi="false" e1="DDI-PubMed.31288895.s24.e0" e2="DDI-PubMed.31288895.s24.e1" /><pair ddi="false" e1="DDI-PubMed.31288895.s24.e0" e2="DDI-PubMed.31288895.s24.e2" /><pair ddi="false" e1="DDI-PubMed.31288895.s24.e1" e2="DDI-PubMed.31288895.s24.e1" /><pair ddi="false" e1="DDI-PubMed.31288895.s24.e1" e2="DDI-PubMed.31288895.s24.e2" /></sentence><sentence text="80 % of metabolic behaviour in change with bioavailability decreased by 38" /><sentence text="11 % that took effect to flucloxacillin metabolism for liver injury in CPY3A4 poor metabolic polymorphisms"><entity charOffset="25-39" id="DDI-PubMed.31288895.s26.e0" text="flucloxacillin" /></sentence><sentence text=" SMS can be an optional method applied to characterize and analyze pharmacokinetic profiles" /><sentence text="" /></document>